Xencor | XNCR - Net Income


Xencor reported $-6.65M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alnylam Pharmaceuticals USD 186.42M 64.66M Dec/2025
Amgen USD 1.33B 1.88B Dec/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
AstraZeneca USD 2.33B 207M Dec/2025
Biogen USD 466.5M 168.3M Sep/2025
Bristol-Myers Squibb USD 1.09B 1.11B Dec/2025
Cytokinetics USD -183.03M 123.15M Dec/2025
GlaxoSmithKline GBP 636M 1.38B Dec/2025
J&J USD 5.24B 119M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD 2.96B 2.82B Dec/2025
Novartis USD 2.41B 1.52B Dec/2025
Pfizer USD -1.65B 5.19B Dec/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
Xencor USD -6.65M 626K Dec/2025